⚕ GalenOps field
←

SITE015-0087

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-06-05

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 148); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-01 (study day 230); relationship: Y

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 347); relationship: not assessed

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-03-01 (study day 624); relationship: not assessed

severe serious assessed

Grade 4 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-03-04 (study day 627); relationship: N; serious criteria: life-threatening

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 650); relationship: N

Data queries

No data queries.